# Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

> **NCT03719300** · PHASE2 · TERMINATED · sponsor: **Anchiano Therapeutics Israel Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Non-muscle Invasive Bladder Cancer (NMIBC)

## Interventions

- **DRUG:** inodiftagene vixteplasmid

## Key facts

- **NCT ID:** NCT03719300
- **Lead sponsor:** Anchiano Therapeutics Israel Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-20
- **Primary completion:** 2019-11-18
- **Final completion:** 2019-12-18
- **Target enrollment:** 32 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03719300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03719300, "Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03719300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*